Clinical Trial Update: Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects [Phase 1]

View source ↗

Summary

A Phase 1 study comparing the bioavailability of two nevirapine extended-release formulations to Viramune in HIV-1 infected subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Nevirapine Extended-Release Formulation A (nevirapine)
• Nevirapine Extended-Release Formulation B (nevirapine)
• Viramune (Nevirapine)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: HIV Infections | Phase 1 | Status: COMPLETED